Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles

Journal of Drug Targeting

Volumn 21, Issue 4, 2013, Pages 354-366

  Singh, Neha D ^a   Banga, Ajay K ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Dose titration; Iontophoresis; Modulated delivery; Parkinson's disease; Ropinirole; Skin microporation; Transdermal

Indexed keywords

ROPINIROLE;

ANIMAL EXPERIMENT; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENSITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; IN VITRO STUDY; IONTOPHORESIS; MICRONEEDLE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SKIN PERMEABILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIPARKINSON AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG DELIVERY SYSTEMS; INDOLES; IONS; IONTOPHORESIS; NEEDLES; SKIN; SKIN ABSORPTION; SWINE;

EID: 84877138473     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.757768     Document Type: Article

References (48)

1. Parkinson's Disease Foundation I. Statistics on Parkinson's. 2012 ed. 2012.
2. Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci 2009;30:41-7.
3. Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003;53:S16-23; discussion S23-5.
4. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93.
5. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008;23:75-80.
6. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23:S2-7.
7. Im JH, Ha JH, Cho IS. Lee MC. 2003. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. J Neurol 2003;250:90-6.
8. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997;49:393-9.
9. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13:39-45.
10. Levy G. Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin Pharmacokinet 1998;34:323-33.
11. Nashatizadeh MM, Lyons KE, Pahwa R. A review of ropinirole prolonged release in Parkinson's disease. Clin Interv Aging 2009;4:179-86.
12. Kim HJ, Jeon BS, Lee WY, et al. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol 2011;11:100.
13. Sanford M, Scott LJ. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. CNS Drugs 2011;25:699-719.
14. Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol 1998;21:169-75.
15. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-15.
16. Uchida N, Takagi Y, Takada Y. Adhesive patch-containing package bag and method for storing adhesive patch. European Patent Application 2012;13/265:418.
17. Banga AK. Electrically assisted transdermal and topical drug delivery. Bristol, PA: Taylor and Francis; 1998.
18. Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev 2001;46:281-305.
19. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004;56:619-58.
20. Vemulapalli V, Yang Y, Siddoju S, et al. In vitro and in vivo iontophoretic transdermal delivery of an anti-parkinsonian agent. Int J Pharm 2011;420:20-5.
21. Nugroho AK, Li G, Grossklaus A, et al. Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro. J Control Release 2004;96:159-67.
22. Nugroho AK, Li GL, Danhof M., et al. Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration. Pharm Res 2004;21:844-50.
23. Nugroho AK, Li L, Dijkstra D, et al. Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. J Control Release 2005;103:393-403.
24. Van Der Geest R, Danhof M, Bodde HE. Iontophoretic delivery of apomorphine. I: in vitro optimization and validation. Pharm Res 1997;14:1798-803.
25. Luzardo-Alvarez A, Delgado-Charro MB, Blanco-Mendez J. Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation. Pharm Res 2001;18:1714-20.
26. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004;56:581-7.
27. Singh N, Kalluri H, Herwadkar A, et al. Transcending the skin barrier to deliver peptides and proteins using active technologies. Crit Rev Ther Drug Carrier Syst 2012;29:265-98.
28. Kalluri H. Banga AK. Formation and closure of microchannels in skin following microporation. Pharm Res 2011;28:82-94.
29. Wu XM, Todo H, Sugibayashi K. Enhancement of skin permeation of high molecular compounds by a combination of microneedle pretreatment and iontophoresis. J Control Release 2007;118:189-95.
30. Katikaneni S, Badkar A, Nema S, Banga AK. Molecular charge mediated transport of a 13 kD protein across microporated skin. Int J Pharm 2009;378:93-100.
31. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 2000;60:115-37.
32. Beier C, Wilhelm M. Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole. 2004. 10/485043.
33. Banga AK. Microporation applications for enhancing drug delivery. Expert Opin Drug Deliv 2009;6:343-54.
34. Kolli CS, Banga AK. Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm Res 2008;25:104-13.
35. Li G, Badkar A, Nema S, et al. In vitro transdermal delivery of therapeutic antibodies using maltose microneedles. Int J Pharm 2009;368:109-15.
36. Badran MM, Kuntsche J, Fahr A. Skin penetration enhancement by a microneedle device (Dermaroller) in vitro: dependency on needle size and applied formulation. Eur J Pharm Sci 2009;36:511-23.
37. Kaushik S, Hord AH, Denson DD, et al. Lack of pain associated with microfabricated microneedles. Anesth Analg 2001;92:502-4.
38. Kah M. Brown CD. LogD: lipophilicity for ionisable compounds. Chemosphere 2008;72:1401-8.
39. Banks SL, Pinninti RR, Gill HS, et al. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharm Res 2008;25:1677-85.
40. Banga AK. Transdermal and intradermal delivery of therapeutic agents: Application of physical technologies. London: Taylor and Francis; 2011.
41. Steiger M. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease. Eur J Neurol 2008;15:6-15.
42. Garland MJ, Caffarel-Salvador E, Migalska K. Dissolving polymeric microneedle arrays for electrically assisted transdermal drug delivery. J Control Release 2012;159:52-9.
43. Vemulapalli V, Yang Y, Friden PM, Banga AK. Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J Pharm Pharmacol 2008;60:27-33.
44. Badkar AV, Smith AM, Eppstein JA, Banga AK. Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats. Pharm Res 2007;24:1389-95.
45. Mudry B, Guy RH, Delgado-Charro MB. Transport numbers in transdermal iontophoresis. Biophys J 2006;90:2822-30.
46. Phipps JB, Gyory JR. Transdermal ion migration. Adv Drug Deliv Rev 1992;9:137-76.
47. Fatouros DG, Groenink HW, De Graaff AM. Visualization studies of human skin in vitro/in vivo under the influence of an electrical field. Eur J Pharm Sci 2006;29:160-70.
48. Calatayud-Pascual MA. Balaguer-Fernandez C, Serna-Jimenez CE, Effect of iontophoresis on in vitro transdermal absorption of almotriptan. Int J Pharm 2011;416:189-94.